Clinical Trial: GST101 in Participants With RAS-Mutant Advanced Solid Tumors

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07868172) titled 'GST101 in Participants With RAS-Mutant Advanced Solid Tumors' on Oct. 01.

Brief Summary: This is an open-label, multicenter Phase I/II trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of oral GST101 in adult participants with RAS-mutant advanced solid tumors.

Phase I consists of dose escalation and dose-expansion parts. Dose escalation uses accelerated titration design combined with 3+3 design to determine maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Safety, dose-limiting-toxicity (DLT), PK and preliminary efficacy will be assessed.

Phase II (indication-exploration) enrol...